Trevor R.P. Cole

Prof. Dr. Trevor R.P. Cole

West Midlands Regional Genetics Service, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B15 2TG, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AGAmy Gerrish
Amy Gerrish
HJHelen Jenkinson
Helen Jenkinson
Trevor R.P. ColeTrevor R.P. Cole
Trevor R.P. Cole
Retinoblastoma is a childhood eye cancer, mainly caused by mutations in the RB1 gene, which can be somatic or constitutional. Unlike many other cancers, tumour biopsies are not performed due to the risk of tumour dissemination. As a result, until recently, somatic genetic analysis was only possible if an affected eye was removed as part of a treatment. Several recent proof of principle studies have demonstrated that the analysis of tumour-derived cell-free DNA, either obtained from ocular fluid or blood plasma, has the potential to advance the diagnosis and influence the prognosis of retinoblastoma patients. It has been shown that a confirmed diagnosis is possible in retinoblastoma patients undergoing conservative treatment. In vivo genetic analysis of retinoblastoma tumours is also now possible, allowing the potential identification of secondary genetic events as prognostic biomarkers. In addition, noninvasive prenatal diagnosis in children at risk of inheriting retinoblastoma has been developed. Here, we review the current literature and discuss the potential impact of cell-free DNA analysis on both the diagnosis and treatment of retinoblastoma patients and their families.

30 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAmy Gerrish
Amy Gerrish
BBBenjamin Bowns
Benjamin Bowns
CMChipo Mashayamombe-Wolfgarten
Chipo Mashayamombe-Wolfgarten
EYElizabeth C. Young
Elizabeth C. Young
SCSamantha Court
Samantha Court
SAStephanie Allen
Stephanie Allen
Retinoblastoma, the most common childhood eye cancer, presents in two forms: heritable or sporadic. Heritable retinoblastoma is caused by a germline mutation in the RB1 gene. Early diagnosis of children at risk of inheriting an RB1 mutation is crucial to achieve optimal clinical outcome. Currently, the majority of genetic testing is performed on newborns, which has multiple disadvantages for both families and the healthcare system. We have developed a non-invasive prenatal diagnosis (NIPD) service for retinoblastoma, available from 8 weeks’ gestation, which uses a combination of massively parallel sequencing (MPS) techniques, dependent on the inheritance model. Detection of paternal or suspected de novo RB1 variants is achieved through amplicon-based MPS. NIPD of a fetus at risk of maternal inheritance is performed using capture-based targeted sequencing and relative haplotype dosage analysis. In addition, we show proof of principle of how capture-based sequencing can be used for de novo variants unsuitable for amplicon-based testing. In total, we report the NIPD of 15 pregnancies, results of which show 100% concordance with all postnatal testing performed at the time of publication (n = 12) with remaining pregnancies ongoing. NIPD of retinoblastoma therefore offers a viable alternative to newborn genetic testing.

19 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AGAmy Gerrish
Amy Gerrish
CMChipo Mashayamombe-Wolfgarten
Chipo Mashayamombe-Wolfgarten
ESEdward Stone
Edward Stone
CRClaudia Román-Montañana
Claudia Román-Montañana
JAJoseph Abbott
Joseph Abbott
Trevor R.P. ColeTrevor R.P. Cole
Trevor R.P. Cole
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected RB1 pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic RB1 pathogenic variants in retinoblastoma patients undergoing conservative treatment.

1 January 2022
Verified
Report
Open access
PDF file
EHEleanor Hay
Eleanor Hay
FEFrances Elmslie
Frances Elmslie
PLPeter Lanyon
Peter Lanyon
Trevor R.P. ColeTrevor R.P. Cole
Trevor R.P. Cole
The Diagnostic Odyssey in rare diseases; a Task and Finish Group report for the Department of Health and Social Care Authors: Eleanor Hay, Frances Elmslie, Peter Lanyon and Trevor Cole April 2021 Keywords: rare diseases, diagnostic odyssey, outpatient diagnostic coding, Tuberous Sclerosis Complex, Bardet Biedl Syndrome, ANCA-associated Vasculitis, NCARDRS INTRODUCTION Background Rare diseases can be defined as life-threatening or chronically debilitating conditions that have a frequency of less than 1 in 2000 in the population at risk. While individually rare, with greater recognition it is apparent that as many as 1 in 17 people will develop a rare disease over their lifetime, equating to approximately 3.5 million people in the UK alone. Over 75% of rare diseases affect children and currently 30% of patients die before reaching their 5th birthday 7. Whilst it is estimated that 80% of rare diseases are genetic in origin, only a quarter of these have had their molecular basis defined. This has led to difficulty in recognising and effectively diagnosing these conditions 7. The journey from initial presentation to the NHS through to receiving an accurate diagnosis is termed the diagnostic odyssey (DO). Whilst many individuals with rare diseases in the UK report excellent and timely patient journeys, a large European study, including a cohort of UK patients, looking at eight rare disease subsets, identified that 25% of patients had to wait between five and thirty years for a final diagnosis 8. In these prolonged diagnostic odysseys, patients may have multiple NHS encounters with a variety of specialists and endure serial and often invasive investigations 4. In a Rare Disease UK survey in 2016, it was found that on average from the time of first symptoms relating to the condition, to a formal diagnosis, individuals consulted five doctors and had three misdiagnoses 20. This is frustrating and stressful for the patient and family and an ineffective and expensive use of resources. A delayed or misdiagnosis may also have serious implications for patient health and lead to missed opportunities for effective intervention. The recently published 2021 Rare Diseases Framework has built on, and superseded, the 2013 UK strategy for Rare Diseases Report. The work and writing underlying this document was completed prior to the publication of the 2021 framework. In both the 2013 and 2021 documents however, a key recommendation is to reduce diagnostic delay and, in doing so, improve timely access to appropriate intervention4. The 2013 report set out several approaches to achieving this aim, including improved prenatal care and newborn screening programmes and carrier and cascade testing for relatives of individuals with known genetic conditions. Education of health care providers in recognising rare disease and understanding genomic testing was also noted, through massive open online courses (MOOC) and Health Education England funded programmes, ranging from stand-alone modules to full MSc courses in Genomic Medicine. Large sequencing projects, such as the Deciphering Developmental Disorders (DDD) and 100,000 Genomes project, have delivered many new diagnoses to families who have endured long odysseys and has set in motion the development of an NHS clinical whole genome sequencing service, with live clinical testing for selected rare disease phenotypes available from November 2020. Reconfiguration of NHS England laboratories into seven Genomic Laboratory Hubs has additionally met the aim to ensure equal access to high quality genomic testing 4. The 2021 Framework notes that, despite making significant progress, there remain areas for further development 5. The framework outlines a future vision, shared by all four UK nations, to address health inequalities, improve the quality and availability of care, and improve the lives of people living with rare diseases. The four key priorities highlighted include helping patients to get a final diagnosis faster, increasing awareness of rare diseases among healthcare professionals, better coordination of care and improving access to specialist care, treatments and drugs. In the related document, ‘Genome UK: the future of healthcare’, incorporating genomics into routine healthcare for the provision of diagnosis and personalised medicine for rare disease, is also highlighted as one of the three pillars supporting the strategy to create the most advanced genomic healthcare system in the world 6. The framework however, also raises greater awareness that a significant proportion of rare diseases, at least 20%, do not have a genomic aetiology but face many of the same issues. This focus on strategy implementation related to genomic advances reflects the fact that up to 80% of rare diseases are genetic in origin. However, implementation also needs to be inclusive of the needs of the remaining 20% of people living with rare non-genetic diseases, as further emphasized in the 2021 UK Rare Diseases Framework 5. An exemplar for this non-genetic group are the rare autoimmune rheumatic diseases, conditions which predominantly have onset in later life and share multisystem clinical features which occur when the body’s own immune system attacks healthy tissues, akin to “friendly fire”. The unmet needs of people living with these conditions, in particular related to diagnostic delay, coordination of care and lack of knowledge, are highlighted in a 2018 report by the Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) 1. A key finding was that almost half (46%) of the 2300 respondents reported waiting more than three years from first symptom to receiving their correct diagnosis, with fewer than 1 in 10 being diagnosed in less than three months. Of concern, the report did not find evidence of any recent improvement in this delay amongst those diagnosed in the last three years. To inform implementation of the new Framework and to understand whether the UK strategy has been successful in leading to improvements in the DO, there is a need to develop an effective and efficient methodology to measure changes in the DO over time. This is particularly challenging in the case of rare diseases as, by definition, they affect only a small fraction of the population. For example, the small number of cases of some individual conditions may not allow for sufficient statistical power to detect improvements in the DO following any policy implementation. Additionally, collation of data across multiple NHS Trusts presents a logistical challenge. While several definitions of the DO have been proposed, for the purposes of this report we have considered this to: begin at the time point when an individual first seeks NHS care with features (clinical symptoms, examination findings or test results) that are later classified as likely to have been a presenting feature of their rare disease end at the time point of definitive diagnosis, be that clinical, biochemical or genetic We also considered that the DO metric could be further characterised by two inter-dependant components the duration of the odyssey e.g. time from beginning to end the circuitousness of the odyssey e.g. the number of consultations or different specialties involved in that person’s healthcare, from beginning to end The 2015 Policy Innovation Research Unit (PIRU) report sought to address whether an accurate, robust and financially plausible method could be developed that could effectively measure the duration of rare disease diagnostic odysseys and therefore evaluate the impact of interventions and policies 3. Whilst a number of potential measures were considered, including the use of clinical databases, rare disease registries and hospital administrative records, there was no unifying suggestion as to how best to approach this analysis. In 2015/2016 the UK Genetic Testing Network (UKGTN) Rare Disease Service Improvement Working Group evaluated practical solutions to this analysis 4. A small pilot of rare disease patients highlighted the challenges of obtaining and evaluating data when multiple specialities, databases and different hospital trusts were involved. In-house and RD SI working group discussions together with literature reviews illustrated how existing routinely collected healthcare databases, such as the Clinical Practice Research Datalink (CPRD), could potentially be used to obtain data on the duration of the DO. Choice of exemplar conditions Examples of conditions documented in the PIRU systematic review frequently were single system disorders, or disorders which would likely present to a single or small number of specialities 3. Some of the disorders would be detected in national screening programmes (inborn errors of metabolism including congenital hypothyroidism or homocystinuria) or had simple diagnostic tests (Cystic Fibrosis, Duchenne muscular dystrophy or Fabry’s disease) and these were not thought to encompass the true challenges of the diagnostic odyssey in rare disorders 3. We therefore considered that it was important to include multisystem diseases in our pilot, in order to assess variable clinical and temporal presentations to multiple medical specialities at different ages. An initial pilot utilising a manual review of paper records for two rare disorder cases (CHARGE syndrome and Bardet Biedl Syndrome) ascertained that single institution hospital records were too incomplete to provide meaningful data, as patients with rare disorders are often seen in multiple specialities that are frequently not co-located. In addition, a requirement from the pilot was that only those patients with an assured diagnosis be included to ensure that the diagnostic odyssey had come to a “correct end point”. If this has not been the case a rapid but incorrect diagnosis would mask the true length of the DO. In this report three rare conditions were chosen as exemplars for the DO faced by individuals and their families. In two (Tuberous Sclerosis Complex and Bardet Biedl syndrome) the diagnosis could be confirmed with genetic testing. In the third, a non-genetic disorder (ANCA-associated Vasculitis) clinical and biological markers could provide assurance of the correct diagnosis. The DO incurred by patients with these three rare genetic and non-genetic conditions are felt to be representative of many rare diseases and highlight the challenges of securing a timely diagnosis. Description of conditions selected Tuberous Sclerosis Complex Tuberous sclerosis Complex (TSC) is an extremely variable multi-system genetic disorder that affects around 8000 people in the UK and has an incidence of 1 in 6000-10,000. It is characterised by abnormalities of the skin, brain, eye, kidney and heart and is often associated with seizures and a range of cognitive and neurodevelopmental disorders 10. Complications such as treatment resistant epilepsy, renal angiomyolipoma and an overgrowth of smooth muscle in the lungs (LAM) can significantly reduce life expectancy. Advances in genetic sequencing technologies over the last decade have improved the molecular diagnostic yield such that, in 75-90% of patients, a pathogenic (disease-causing) gene change in TSC1 or TSC2 is identified. These gene changes may occur for the first time in an individual or be inherited in an autosomal dominant fashion from a variably affected parent, who may not be aware that they have the condition. In the 10-25% without a recognised gene change, the 2012 International Tuberous Sclerosis Complex Diagnostic Criteria (11 major and 6 minor features) provide guidance on the clinical diagnosis of TSC 10. In the past, presentation of TSC was often in childhood following the onset of a seizure disorder. As there is greater recognition of key features of the condition, presentations have now broadened to include antenatal referral for cardiac rhabdomyomas, children and adults with hypopigmented patches, young women with renal angiomyolipomata and family members of a relative with a known TSC1/2 mutation. Unfortunately, more mildly affected individuals may go decades without a diagnosis due to the insidious onset of many non-specific symptoms that are not recognised in aggregate 2. Pathogenic variants can now be used independently of clinical signs to diagnose individuals with TSC, facilitating earlier diagnosis in children in whom few clinical signs may be evident. This is important, as earlier access to surveillance and treatment has the potential to improve outcomes of individuals with TSC and reduce the rate of complications. In the TS2000 study, the impact of earlier diagnosis and intervention of TSC-induced infantile spasms was evident in an improvement in neurodevelopmental outcomes 10. A confirmed diagnosis of TSC can also entitle the individual to management with oral or topical mTOR inhibitors, such as Everolimus, that target the specific pathway disrupted in TSC  10. Additionally, a genetic diagnosis can enable other members of the family to be tested and permit prenatal or preimplantation genetic diagnosis. Bardet Biedl Syndrome Bardet Biedl syndrome (BBS) is another multi-system genetic condition with a prevalence in non-consanguineous populations of between 1 in 100,000 and 1 in 160,000. The features of BBS are variable, though most develop truncal obesity and a specific eye phenotype that leads to night blindness in childhood, progressing to loss of visual acuity. 75% of adults become legally blind, often from adolescence. Additional features include postaxial polydactyly, developmental delay, intellectual disability, hypogonadotrophic hypogonadism in males, genitourinary abnormalities in females and structural or functional impairment of the kidneys 9. Diagnosis can be made on the basis of clinical features, but more recently the genetic basis of BBS has been further elucidated. To date, 19 genes for BBS have been documented, although around 40% of diagnoses are accounted for by BBS1 and BBS10 alone and 20% have no pathogenic variant detected 9, suggesting that further genes may be responsible. Inheritance is autosomal recessive and parents are usually carriers of the gene change and therefore have a 25% (1 in 4) chance of recurrence in future pregnancies. As many of the features of BBS are non-specific (developmental delay and obesity) or do not manifest until later in childhood (visual and renal issues), diagnosis is often delayed. Whilst there is currently no management to prevent or reverse the eye changes, early diagnosis can improve visual and psychological outcomes by preparing children for visual loss through Braille/visual support. Prompt access to educational support and surveillance and intervention for endocrine and renal manifestations is also beneficial 9 . Understanding the cause of children’s weight gain and targeting this early can additionally reduce or prevent the associated co-morbidities, such as hypertension and diabetes mellitus. Finally, recognising the genetic cause in an individual permits accurate counselling of the family on recurrence and provides the option for prenatal testing or pre-implantation genetic diagnosis, if desired. ANCA-associated Vasculitis The rare autoimmune rheumatic diseases can be grouped into two categories, Autoimmune Connective Tissue Diseases (e.g. Systemic Lupus Erythematosus, Systemic Sclerosis, Myositis, and Sjogren’s Syndrome) and Systemic Vasculitis (e.g. ANCA-associated Vasculitis, Giant Cell Arteritis, Takayasu’s Arteritis, Behçets Syndrome). ANCA-associated vasculitis (AAV) was selected as an ideal exemplar for these conditions. AAV is a late-onset (median age 55 years) non-genetic condition in which vascular inflammation leads to irreversible organ damage to kidneys, lungs, gut, peripheral nerves, hearing and vision. The estimated incidence is 23 per million person-years 14 and more than half of the 1500 new cases each year are diagnosed during an episode of unscheduled emergency in-patient care 15. The estimated prevalence is 25/100,000 persons, with 13,000 people living with AAV in the UK 14. AAV comprises three sub-types that share overlapping clinical features; Granulomatosis with Polyangiitis (GPA, previously called Wegener’s Granulomatosis), Microscopic Polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA, previously called Churg Strauss Syndrome), with each type having their own ICD code that maps one-one with a single orphacode. Diagnosis is associated with the detection of autoantibodies directed against proteins within the cytoplasm of neutrophil white blood cells (Antineutrophil cytoplasmic antibodies, ANCA), and it is likely that these antibodies are involved in pathogenesis. Diagnosis is established by ANCA detection, in the context of appropriate clinical features, supported by tissue biopsy. Initial treatment to induce remission is high dose steroids and either the chemotherapeutic drug cyclophosphamide (AAV is the most common indication for the use of non-cancer chemotherapy) or rituximab, a high-cost biologic commissioned by NHS England for this indication. Optimal care also involves coordination across a range of disciplines, including rheumatology, nephrology, respiratory, dermatology, ENT and ophthalmology. AAV has the highest mortality of any rare autoimmune disease, with one in seven people dying within a year after diagnosis 13. Reducing diagnostic delay and improving outcomes have been identified as top priorities by people living with vasculitis. L ike many rare diseases, it can be difficult to diagnose, mimicking other conditions, including infection and malignancy. The initial presentation can be nonspecific and include sinusitis, fatigue, joint pain, weight loss, fever, cough and skin rashes, or renal failure, which is often asymptomatic. Delays in diagnosis are associated with greater risk of irreversible organ damage, which adversely affects clinical outcomes and also increases costs to the NHS, including renal replacement therapy, which is required by 20% of people who survive the first year after diagnosis. Recent research undertaken in primary care records has found evidence of increased health-seeking behaviour in the five years before diagnosis amongst people subsequently diagnosed with GPA subtype compared with those without this diagnosis 21 This study also emphasised the difficulties of developing risk prediction models in primary care and highlighted opportunities for earlier diagnosis in secondary care, which dovetails with the work in this pilot. This accords with the 2018 RAIRDA report; of the respondents with any type of vasculitis, more than 40% reported a delay of at least one year from onset of symptoms to diagnosis. These complementary studies support the existence of a diagnostic odyssey of ill health for a long time without a diagnosis, often with this only being achieved when there is further clinical deterioration leading to unscheduled emergency admission 15. Whilst progress is being made, to address the remaining diagnostic delay for rare diseases it will be important to improve education for healthcare professionals, increase population awareness of the condition and develop condition specific pathways to support diagnosis, including genetic testing. Aims The Diagnostic Odyssey Task and Finish Group aims to propose standard methods for estimating the diagnostic odyssey for individuals with rare diseases. This methodology would then facilitate appropriate measurements...